We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

42 hedge funds and large institutions have $10.1M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

2% more funds holding

Funds holding: 41 → 42 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

28% less capital invested

Capital invested by funds: $14.1M → $10.1M (-$3.97M)

Holders
42
Holders Change
+1
Holders Change %
+2.44%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
9
Reduced
8
Closed
7
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
MCM
MAI Capital Management
Ohio
+$122K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$38.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$18.2K
4
XT
XTX Topco
Cayman Islands
+$16.4K
5
UBV
United Bank (Virginia)
Virginia
+$13.3K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$209K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$96K
3
BCM
Bridgeway Capital Management
Texas
-$69.2K
4
Jane Street
Jane Street
New York
-$59K
5
B
Bailard
California
-$48.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bourgeon Capital Management
Connecticut
$7.8K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$5.26K +$23 +17 +0.3%
RM
28
RP Management
New York
$3.85K – – –
IWP
29
IAG Wealth Partners
Wisconsin
$3.12K – – –
Barclays
30
Barclays
United Kingdom
$2.77K – – –
Simplex Trading
31
Simplex Trading
Illinois
$1K +$1.55K +1,142 New
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$1K +$1.64K +1,205 +407%
JP Morgan Chase
33
JP Morgan Chase
New York
$750 – – –
Wells Fargo
34
Wells Fargo
California
$385 +$37 +27 +8%
ITIM
35
Indiana Trust & Investment Management
Indiana
$208 +$271 +200 New
UBS Group
36
UBS Group
Switzerland
$68 +$88 +65 New
NA
37
NewEdge Advisors
Louisiana
$15 +$19 +14 New
PA
38
Parallel Advisors
California
$8 – – –
AA
39
Addison Advisors
Vermont
$5 – – –
PO
40
Private Ocean
California
$3 +$4 +3 New
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$2 +$3 +2 New
Jane Street
42
Jane Street
New York
– -$59K -41,854 Closed
HF
43
HRT Financial
New York
– -$24K -17,291 Closed
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
– -$23.7K -16,793 Closed
Two Sigma Advisers
45
Two Sigma Advisers
New York
– -$17.9K -12,719 Closed
Osaic Holdings
46
Osaic Holdings
Arizona
– -$6.12K -4,564 Closed
Group One Trading
47
Group One Trading
Illinois
– -$141 -100 Closed
Fidelity Investments
48
Fidelity Investments
Massachusetts
– -$12 -8 Closed
NS
49
NBC Securities
Alabama
– +$950 +700 New
1
2

VIRX Hedge Fund Activity: Q3 2023 in Review

42 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2023, worth a combined $10.1M — down 28% from $14.1M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VIRX positions and 7 closed out — a net gain of 1 holder — while 9 added to existing stakes and 8 trimmed.

The largest buyer was MAI Capital Management, adding an estimated $122K. The largest seller was BlackRock, cutting an estimated $209K.

  • 42 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2023, up from 41 in Q2 2023.
  • Funds reported $10.1M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2023, down 28% quarter-over-quarter.
  • 8 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2023 and 7 closed out, a net change of +1 holder.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2023 was MAI Capital Management, an estimated $122K added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2023 was BlackRock, an estimated $209K sold.

Based on aggregated 13F filings for Q3 2023.